LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

25.82 -2.79

Buy Sell

Overview

Share price change

24h

Current

Min

25.76

Max

26.03

Key metrics
By Trading Economics
Income	23M 7.4M
Sales	18M 99M
EPS	0.06
Profit margin	7.468
Employees	342
EBITDA	23M 11M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+23.74% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	881M 3.3B
Previous open	28.61
Previous close	25.82

News Sentiment

By Acuity

67%

33%

311 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

12.42 / 14.93 Support & Resistance

Arcutis Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lut 2026, 16:32 UTC

Earnings

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14 lut 2026, 22:02 UTC

Earnings

Looking for Dividends? Consider Europe. -- Barrons.com

14 lut 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:57 UTC

Earnings

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:20 UTC

Earnings

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 lut 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 lut 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 lut 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13 lut 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 lut 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13 lut 2026, 19:51 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:29 UTC

Earnings

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 lut 2026, 18:18 UTC

Acquisitions, Mergers, Takeovers

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 lut 2026, 17:52 UTC

Earnings

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 lut 2026, 17:16 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 17:10 UTC

Acquisitions, Mergers, Takeovers

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 lut 2026, 16:59 UTC

Earnings

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 lut 2026, 16:39 UTC

Acquisitions, Mergers, Takeovers

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 lut 2026, 16:11 UTC

Earnings

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 lut 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13 lut 2026, 15:54 UTC

Earnings

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 lut 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 lut 2026, 15:01 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 lut 2026, 15:00 UTC

Earnings

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 lut 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 lut 2026, 14:44 UTC

Earnings

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 lut 2026, 14:22 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

23.74% upside

12 Months Forecast

Average 32 USD 23.74%

High 37 USD

Low 30 USD

Based on 7 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Arcutis Biotherapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

12.42 / 14.93Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

311 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.